TABLE 4.
Kitchener et al.51 (2014) and Gilham et al.50 (2019) | Pooled HPV persistent | SGTP | GS | HPV(+), then HPV(−) as referent | HPV(−), then HPV(−) as referent |
---|---|---|---|---|---|
≥CIN 2 three-year risk51 | 12.9% | 21.0% | 6.2 | 0.59% | 0.02% |
≥CIN 3 three-year risk51 | 7.0% | 13.5% | 1.7% | 0.17% | 0% |
≥CIN 3 five-year CIR; NILM50 | 7.0 (3.9–12.2) | 11.3 (6.5–19.5) | 0 | 0.13 (0.02–0.90) | 0.05 (0.02–0.11) |
≥CIN 3 ten-year CIR; NILM50 | 8.9 (5.4–14.5) | 13.4 (8.0–22.0) | 1.7 (0.2–11.3) | 0.26 (0.06–1.03) | 0.09 (0.05–0.17) |
≥CIN 3 five-year CIR; low-grade cytologya50 | 14.5 (7.8–26.0) | 23.7 (14.8–36.8) | 5.1 (2.5–10.4) | 1.6 (0.2–10.7) | 0 |
≥CIN 3 ten-year CIR; low-grade cytology50 | 16.2 (9.0–28.0) | 23.7 (14.8–36.8) | 5.9 (3.0–11.4) | 1.6 (0.2–10.7) | 0 |
aLow-grade cytology = ASC-US and LSIL combined.